Skip to main content

Table 2 Biologic and nonbiologic DMARDs use 30 days before and after zoster vaccination (n = 514)

From: The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

  30 days before vaccination Day of vaccination 30 days after vaccination
  n % n % n %
Anti-TNF 40 7.8 32 6.2 40 7.8
   Etanercept 18 3.5 12 2.3 18 3.5
   Adalimumab 11 2.1 9 1.8 11 2.1
   Infliximab 11 2.1 11 2.1 11 2.1
Other biologicsa 4 0.8 4 0.8 4 0.8
Nonbiologic DMARDs       
   Methotrexate 52 10.1 34 6.6 45 8.8
   Sulfasalazine 16 3.1 13 2.5 16 3.1
   Hydroxychloroquine 26 5.1 17 3.3 25 4.9
Azathioprine 1 0.2 1 0.2 1 0.2
Leflunomide 3 0.6 3 0.6 3 0.6
Cyclosporine 7 1.4 6 1.2 7 1.4
6-Mercaptopurine 5 1.0 3 0.6 5 1.0
Oral glucocorticoid 45 8.8 33 6.4 48 9.3
  1. DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aThe categories (columns) are not exclusive (for example, a patient who used anti-TNF therapies continuously during the 60-day period would be counted in all three categories). bAbatacept, rituximab.